Current approaches for diagnosing mitochondrial disorders involve specialist clinical assessment, biochemical analyses and targeted molecular genetic testing. There is now a strong rationale for undertaking first-line genome-wide sequencing, accelerating the speed of diagnosis and avoiding the need for expensive and invasive investigations.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Mitochondrial diseases in Hong Kong: prevalence, clinical characteristics and genetic landscape
Orphanet Journal of Rare Diseases Open Access 02 March 2023
-
A benchmarking of human mitochondrial DNA haplogroup classifiers from whole-genome and whole-exome sequence data
Scientific Reports Open Access 15 October 2021
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$189.00 per year
only $15.75 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Gorman, G. S. et al. Mitochondrial diseases. Nat. Rev. Dis. Primers 2, 16080 (2016).
Vafai, S. B. & Mootha, V. K. Medicine. A common pathway for a rare disease? Science 342, 1453–1454 (2013).
Stewart, J. B. & Chinnery, P. F. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. Nat. Rev. Genet. 16, 530–542 (2015).
Wright, C. F., FitzPatrick, D. R. & Firth, H. V. Paediatric genomics: diagnosing rare disease in children. Nat. Rev. Genet. 19, 253–268 (2018).
Li, M. et al. Transmission of human mtDNA heteroplasmy in the genome of the Netherlands families: support for a variable-size bottleneck. Genome Res. 26, 417–426 (2016).
Acknowledgements
F.L.R. receives support from the Medical Research Council (MRC, UK), Rosetree Foundation, National Institute for Health Research (NIHR) Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust. R.H. is a Wellcome Investigator (109915/Z/15/Z), who receives support from the Wellcome Centre for Mitochondrial Research (203105/Z/16/Z), MRC (MR/N025431/1), the European Research Council (309548), the Wellcome Trust Pathfinder Scheme (201064/Z/16/Z) and the Newton Fund (UK/Turkey, MR/N027302/1). P.F.C. is a Wellcome Trust Senior Fellow in Clinical Science (101876/Z/13/Z) and a UK NIHR Senior Investigator who receives support from the MRC Mitochondrial Biology Unit (MC_UP_1501/2), the MRC Centre for Translational Muscle Disease (G0601943), the Evelyn Trust and the NIHR Biomedical Research Centre based at Cambridge University Hospitals NHS Foundation Trust and the University of Cambridge. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health.
Author information
Authors and Affiliations
Contributions
The authors contributed equally to all aspects of this article.
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
Raymond, F.L., Horvath, R. & Chinnery, P.F. First-line genomic diagnosis of mitochondrial disorders. Nat Rev Genet 19, 399–400 (2018). https://doi.org/10.1038/s41576-018-0022-1
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41576-018-0022-1
This article is cited by
-
Migräne und mitochondriale Erkrankungen
Der Nervenarzt (2024)
-
Migräne und mitochondriale Erkrankungen
Der Schmerz (2023)
-
Mitochondrial diseases in Hong Kong: prevalence, clinical characteristics and genetic landscape
Orphanet Journal of Rare Diseases (2023)
-
A benchmarking of human mitochondrial DNA haplogroup classifiers from whole-genome and whole-exome sequence data
Scientific Reports (2021)
-
Applying genomic and transcriptomic advances to mitochondrial medicine
Nature Reviews Neurology (2021)
